Letrozole-induced reversible acute heart failure.

Letrozole breast cancer heart failure

Journal

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
ISSN: 1477-092X
Titre abrégé: J Oncol Pharm Pract
Pays: England
ID NLM: 9511372

Informations de publication

Date de publication:
13 Sep 2024
Historique:
medline: 14 9 2024
pubmed: 14 9 2024
entrez: 14 9 2024
Statut: aheadofprint

Résumé

Letrozole is an aromatase inhibitor (AI), which suppresses plasma estrogen levels by inhibiting the aromatase enzyme, that causes the conversion of androgens to estrogen in peripheral tissues. There is very few information in the literature regarding the development of acute heart failure after AI use. We would like to report a case of a patient who was started letrozole for hormonal treatment and developed acute heart failure due to this. Fifty-seven-year-old woman with hormone positive breast cancer was operated after neoadjuvant chemotherapy and received radiotherapy. Letrozole treatment was initiated after radiotherapy and the patient presented to the emergency department after two weeks with cough and dyspnea. Ejection fraction decreased to 20% and acute heart failure developed. Letrozole treatment was stopped. Afterwards, improvement in the patient's cardiac functions was observed. Letrozole-induced heart failure was thought to be reversible. Letrozole is one of the most commonly used HT in the treatment of hormone positive breast cancer. It may rarely cause cardiac side effects. It is very important to make patients aware of these issues and to be consulted by cardiology in case of possible cardiac symptoms.

Identifiants

pubmed: 39275843
doi: 10.1177/10781552241284908
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

10781552241284908

Déclaration de conflit d'intérêts

Declaration of conflicting interestsThe authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Auteurs

Serhat Sekmek (S)

Department of Medical Oncology, Ankara Bilkent City Hospital, Ankara, Turkey.

Dogan Bayram (D)

Department of Medical Oncology, Ankara Bilkent City Hospital, Ankara, Turkey.

Ismet Seven (I)

Department of Medical Oncology, Ankara Bilkent City Hospital, Ankara, Turkey.

Perihan Perkin (P)

Department of Medical Oncology, Ankara Bilkent City Hospital, Ankara, Turkey.

Oznur Bal (O)

Department of Medical Oncology, Ankara Bilkent City Hospital, Ankara, Turkey.

Efnan Algin (E)

Department of Medical Oncology, Ankara Bilkent City Hospital, Ankara, Turkey.

Classifications MeSH